Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics receives NYSE American notice of stockholders' equity shortfall

Negative Impact 4 of 5 legal/regulatory Written later

Calidi Biotherapeutics received a notice from NYSE American on September 21, 2026, saying it does not meet the $4.0 million stockholders' equity requirement, as it reported $3.1 million as of June 30, 2026. The company must submit a compliance plan by October 21, 2026, and regain compliance by March 21, 2028, or face delisting proceedings, which raises the risk of delisting for shareholders.

Key points

  • Stockholders' equity was $3.1 million as of June 30, 2026, below the $4.0 million NYSE American requires for companies with net losses in three of four recent fiscal years
  • Notice received September 21, 2026; plan of compliance due October 21, 2026
  • Company must regain compliance by March 21, 2028; delisting proceedings begin if no plan is submitted or accepted
  • Common stock continues to trade as CLDI with a ".BC" designation for noncompliance

The filing

CompanyCalidi Biotherapeutics, Inc. (CLDI)
Form8-K, current report
Filed with the SECSep 25, 2026, 5:15 PM ET
Accession number0001493152-26-044381

Items reported: 3.01 Delisting / Listing Rule Notice8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.